Why are shares of Mayne Pharma Group (ASX:MYX) in news today?

Mayne Pharma Group Ltd (ASX:MYX) has announced its FY22 results. Excluding retail generics, MYX’s  remaining businesses which represent over 80% of reported gross profit, grew 27% compared to the prior corresponding period (pcp).

• FY22 revenues grew 6% compared to FY21 to AU$424.8m
• EBITDA of AU$87.4m, up 32% on pcp, impacted by the non-cash NEXTSTELLIS® deferred consideration reassessment, stock write-downs and other factors.
• Net loss after tax of AU$263.3m led by intangible asset impairments & deferred tax assets write-downs.
• Underlying EBITDA of AU$89.7m excluding NEXTSTELLIS®, up 24% on FY21

The share price of Mayne Pharma Group Ltd was seen trading 0.757% higher at AU$0.332 per share on ASX during the intraday trading session today.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au